GLP-1 News Today: Pancreatitis Warnings & New Weight Loss Pills

The GLP-1 revolution is hitting a crossroads: Novo Nordisk’s Wegovy pill just surpassed 3 million prescriptions, while the UK and Brazil warn of pancreatitis risks. Here’s a grounded look at the risks, results, and what’s next.

Wegovy Pill Prescriptions (Early 2026): Surpassed 3 million, one filled every 5 seconds (Novo Nordisk) · Patients Who Discontinue GLP-1s Within Year 1: Approximately 40-50%, per insurance claims data (Blue Cross / various studies) · Average Weight Loss in 3 Months: 5-10% of total body weight in clinical trials (NEJM) · Countries Issuing Pancreatitis Warnings (2026): United Kingdom and Brazil issued formal alerts (Nature, Feb 2026)

Five key facts, one pattern: the GLP-1 landscape is moving fast on both efficacy and safety fronts.

Why are people stopping GLP-1?

• Up to 40–50% of patients stop taking GLP-1 drugs within the first year, according to insurance claims data reviewed by Medscape (medical news outlet).

Understanding the high discontinuation rate

• Side effects, cost, and plateauing results are the top reasons patients discontinue GLP-1 therapy, reports Medscape.

Side effects driving people away

• Nausea, vomiting, and diarrhea are the most commonly reported side effects, noted in the Cleveland Clinic Journal of Medicine.

Celebrity influence: Why Amy Schumer stopped

• Amy Schumer publicly stated she stopped Ozempic because of severe side effects, which influenced public perception (CBS News).

The implication: The high dropout rate signals a need for better side-effect management and cost solutions to sustain treatment.

What happens when patients stop taking GLP-1 drugs?

• A meta-analysis reported that people stopping semaglutide or tirzepatide regained an average of 9.9 kilograms in the first year (TCTMD (cardiology news outlet)).

The weight regain phenomenon

• A review of 37 studies found that people regained around 0.4 kilograms per month after stopping the drugs (ScienceAlert). Regain is roughly 4x faster than after ending diet-and-exercise-only weight loss efforts.

Metabolic considerations

• The biology that drives weight regain returns when treatment stops, as noted in a 2026 telehealth guide (TeleDirectMD).

Expert advice on how to stop safely

• Experts recommend tapering off GLP-1s under medical supervision while maintaining diet and exercise to slow weight regain (Everyday Health).

The pattern: Without a structured exit plan, patients risk losing all progress – a stark contrast to the initial promise.

What is the new weight-loss drug in 2026?

• Novo Nordisk’s oral semaglutide (Wegovy pill) surpassed 3 million prescriptions in early 2026, making it the first oral GLP-1 blockbuster (Novo Nordisk press release).

The rise of oral GLP-1 medications

• Oral semaglutide is the only GLP-1 receptor agonist available in pill form, according to GoodRx (pharmacy savings platform).

Novo Nordisk’s Wegovy pill

• A prescription is filled roughly every 5 seconds, as reported in the company’s press release.

What’s next in the pharmaceutical pipeline

• Next-generation drugs like retatrutide and orforglipron are showing >20% average weight loss in trials (The Lancet / Eli Lilly).

What this means: The real breakthrough will come when a drug can maintain weight loss after discontinuation – something no GLP-1 has yet achieved.

What is the downside of GLP-1?

• Common side effects are gastrointestinal, but serious complications include pancreatitis and rare overdoses (UK GOV.UK Drug Safety Update).

Common side effects vs. serious risks

• Nausea, vomiting, and diarrhea affect up to 40% of users (Cleveland Clinic Journal of Medicine).

Pancreatitis and overdose warnings

• In January 2026, the UK issued strengthened warnings that GLP-1 drugs can cause acute pancreatitis, including rare necrotising and fatal cases (UK GOV.UK Drug Safety Update). Brazil followed with similar alerts (Nature).

Long-term safety concerns

• The FDA labels include a warning to stop treatment promptly if pancreatitis is suspected (Cleveland Clinic Journal of Medicine).

The catch: Even as efficacy improves, the safety picture remains incomplete – especially for long-term use beyond five years.

How much weight can you lose on GLP-1 in 3 months?

• Clinical trials report an average weight loss of 5-10% of total body weight within the first three months (ClinicalTrials.gov).

Clinical trial averages

• In the STEP trials, participants on semaglutide lost about 7% of body weight by week 12 (PubMed).

Factors influencing individual results

• Results vary significantly based on dosage, adherence, diet, and exercise (Everyday Health).

Real-world examples: celebrities and patients

• Kelly Clarkson has attributed significant weight loss in part to GLP-1 medications, as reported by CBS News.

The pattern: Early results are strong, but individual variability means patients should set realistic expectations and track personal progress.

What is the future of GLP-1 drugs?

• Experts predict that oral formulations will surpass injections in popularity within five years (GoodRx).

Oral drugs dominating the market

• Novo Nordisk’s oral pill is already the most prescribed GLP-1 in pill form.

The potential for even greater weight loss

• Retatrutide, a triple agonist, is showing >20% weight loss in phase 2 trials (The Lancet).

Addressing the long-term safety concerns

• Regulatory bodies and researchers are monitoring long-term outcomes to ensure safety as the drugs become more widely used (FDA).

The implication: The future depends on solving the sustainability puzzle – either through maintenance protocols or drugs that reset metabolic set points.

GLP-1 timeline

• 2005 – FDA approves first GLP-1 drug (exenatide) for type 2 diabetes (FDA)
• 2014–2017 – Liraglutide approved for diabetes (Victoza) and obesity (Saxenda) (PubMed)
• 2021 – Semaglutide (Ozempic/Wegovy) becomes widely known, leading to shortages (BBC News)
• 2024 – Zepbound (tirzepatide) approved, adding competition (FDA)
• Early 2026 – Wegovy oral pill reaches 3 million prescriptions (Novo Nordisk)
• February 2026 – UK and Brazil issue pancreatitis warnings (Nature)

“Wegovy prescriptions surpass 3 million, one filled roughly every 5 seconds.”

— Novo Nordisk, press release, 2026

“The United Kingdom and Brazil have issued warnings about a possible link between GLP-1 weight-loss drugs and pancreatic inflammation.”

— Nature, February 2026

“Lifestyle changes must accompany medication to prevent weight regain. The drugs don’t cure obesity; they treat it.”

— Expert comment, compiled from Everyday Health

For patients in the U.S. and Europe, the choice is clear: GLP-1 drugs offer powerful weight loss, but they come with risks and a long-term commitment. The smartest approach is to start with a clear plan for how to stop, or accept that for many, this is a therapy for life.